Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use
Primary Purpose
Medication Understanding, Diabetes, Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Enhanced Label
Sponsored by

About this trial
This is an interventional health services research trial for Medication Understanding
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Type II diabetes or hypertension in their medical chart
- Spanish speaking
- 30 years or older
Exclusion Criteria:
- Uncorrectable hearing or visual impairment.
- Too ill to participate
Sites / Locations
- Northwestern University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Enhanced Label
Standard Label
Arm Description
Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
Subjects in this arm will receive their prescriptions labeled with a standard label.
Outcomes
Primary Outcome Measures
Understanding of prescription medication
Difference in understanding and comprehension of medication use as compared to control.
Secondary Outcome Measures
Change in HbA1c or blood pressure readings
Full Information
NCT ID
NCT01200849
First Posted
September 2, 2010
Last Updated
November 17, 2014
Sponsor
Northwestern University
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
1. Study Identification
Unique Protocol Identification Number
NCT01200849
Brief Title
Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use
Official Title
Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University
Collaborators
Agency for Healthcare Research and Quality (AHRQ)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The overall objective of this study is to test the efficacy of an evidence-based, enhanced Rx container label design to improve Spanish speaking patients' understanding of instructions for use.
Detailed Description
The investigators will conduct a randomized controlled trial (N=960) to evaluate the efficacy of the enhanced Rx container label to improve, Spanish speaking, diabetic and/or hypertensive patients' understanding of actual prescribed medicines, compared to a standard label format. Spanish-speaking patients with type II diabetes and/or hypertension at safety-net clinics affiliated with one central-fill pharmacy (Nova Scripts Central - NSC) receive all their prescribed medicines from this location. Recruited diabetic and/or hypertensive subjects in this study will be randomly assigned to either intervention (enhanced Rx container label) or control (standard Rx label). All pill-form, regular dosing schedule medicines, including diabetes and hypertensive (i.e. ACE inhibitor) medicines associated with patients' treatment will be labeled according to study arm by the central-fill pharmacy. Study subjects will be interviewed at the time of dispensing the prescribed medicines at the clinic, again three months later (dispensing of refill), and finally nine months after baseline (dispensing of refill). Pharmacy refill data and medical record information - linked at these clinics - will be collected for exploratory analyses. Patients' ability to read and demonstrate Rx label instructions, including auxiliary warnings, will be the primary outcomes for this aim. Data from the actual use trial will be processed, reviewed, analyzed (in order of hypotheses), and reports prepared during the final months of this last phase of the study. We anticipate several manuscripts to be developed as a result of this project, supported by the diverse key personnel and collaborating faculty enlisted.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Medication Understanding, Diabetes, Hypertension
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
420 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Enhanced Label
Arm Type
Experimental
Arm Description
Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
Arm Title
Standard Label
Arm Type
No Intervention
Arm Description
Subjects in this arm will receive their prescriptions labeled with a standard label.
Intervention Type
Other
Intervention Name(s)
Enhanced Label
Intervention Description
A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
Primary Outcome Measure Information:
Title
Understanding of prescription medication
Description
Difference in understanding and comprehension of medication use as compared to control.
Time Frame
Baseline, 3 month follow-up, 9 month follow-up
Secondary Outcome Measure Information:
Title
Change in HbA1c or blood pressure readings
Time Frame
Baseline, 3 month follow-up, 9 month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of Type II diabetes or hypertension in their medical chart
Spanish speaking
30 years or older
Exclusion Criteria:
Uncorrectable hearing or visual impairment.
Too ill to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Wolf, Phd, MPH
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
27542666
Citation
Wolf MS, Davis TC, Curtis LM, Bailey SC, Knox JP, Bergeron A, Abbet M, Shrank WH, Parker RM, Wood AJ. A Patient-Centered Prescription Drug Label to Promote Appropriate Medication Use and Adherence. J Gen Intern Med. 2016 Dec;31(12):1482-1489. doi: 10.1007/s11606-016-3816-x. Epub 2016 Aug 19.
Results Reference
derived
Learn more about this trial
Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use
We'll reach out to this number within 24 hrs